These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25064374)

  • 1. Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities.
    Waterhouse DN; Sutherland BW; Santos ND; Masin D; Osooly M; Strutt D; Ostlund C; Anantha M; Harasym N; Manisali I; Wehbe M; Bally MB; Webb MS
    Invest New Drugs; 2014 Dec; 32(6):1071-82. PubMed ID: 25064374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.
    Neijzen R; Wong MQ; Gill N; Wang H; Karim T; Anantha M; Strutt D; Waterhouse D; Bally MB; Tai IT; Ng SS; Yapp DT
    J Control Release; 2015 Feb; 199():72-83. PubMed ID: 25497312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model.
    Verreault M; Strutt D; Masin D; Anantha M; Waterhouse D; Yapp DT; Bally MB
    J Control Release; 2012 Feb; 158(1):34-43. PubMed ID: 22001870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore C™) and 5-fluorouracil.
    Hare JI; Neijzen RW; Anantha M; Dos Santos N; Harasym N; Webb MS; Allen TM; Bally MB; Waterhouse DN
    PLoS One; 2013; 8(4):e62349. PubMed ID: 23626804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine.
    Verreault M; Strutt D; Masin D; Anantha M; Yung A; Kozlowski P; Waterhouse D; Bally MB; Yapp DT
    BMC Cancer; 2011 Apr; 11():124. PubMed ID: 21477311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of the transition metal copper and the ionophore A23187 in the development of Irinophore C™.
    Patankar N; Anantha M; Ramsay E; Waterhouse D; Bally M
    Pharm Res; 2011 Apr; 28(4):848-57. PubMed ID: 21181548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic mechanisms for reduced toxicity of irinotecan by coadministered thalidomide.
    Yang XX; Hu ZP; Chan SY; Duan W; Ho PC; Boelsterli UA; Ng KY; Chan E; Bian JS; Chen YZ; Huang M; Zhou SF
    Curr Drug Metab; 2006 May; 7(4):431-55. PubMed ID: 16724931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
    Verreault M; Wehbe M; Strutt D; Masin D; Anantha M; Walker D; Chu F; Backstrom I; Kalra J; Waterhouse D; Yapp DT; Bally MB
    J Control Release; 2015 Dec; 220(Pt A):348-357. PubMed ID: 26528901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of irinotecan-induced diarrhea by oral sodium bicarbonate and influence on pharmacokinetics.
    Tamura T; Yasutake K; Nishisaki H; Nakashima T; Horita K; Hirohata S; Ishii A; Hamano K; Aoyama N; Shirasaka D; Kamigaki T; Kasuga M
    Oncology; 2004; 67(5-6):327-37. PubMed ID: 15713987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion.
    Kurita A; Kado S; Kaneda N; Onoue M; Hashimoto S; Yokokura T
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):349-60. PubMed ID: 12904895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A risk-benefit assessment of irinotecan in solid tumours.
    Siu LL; Rowinsky EK
    Drug Saf; 1998 Jun; 18(6):395-417. PubMed ID: 9638386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modified irinotecan hydrochloride (CPT-11) administration schedule improves induction of delayed-onset diarrhea in rats.
    Kurita A; Kado S; Kaneda N; Onoue M; Hashimoto S; Yokokura T
    Cancer Chemother Pharmacol; 2000; 46(3):211-20. PubMed ID: 11021738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed.
    Masi G; Falcone A; Di Paolo A; Allegrini G; Danesi R; Barbara C; Cupini S; Del Tacca M
    Clin Cancer Res; 2004 Mar; 10(5):1657-63. PubMed ID: 15014016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of thalidomide on gastrointestinal toxic effects of irinotecan.
    Govindarajan R; Heaton KM; Broadwater R; Zeitlin A; Lang NP; Hauer-Jensen M
    Lancet; 2000 Aug; 356(9229):566-7. PubMed ID: 10950238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
    Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
    J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
    Rothenberg ML; Cox JV; DeVore RF; Hainsworth JD; Pazdur R; Rivkin SE; Macdonald JS; Geyer CE; Sandbach J; Wolf DL; Mohrland JS; Elfring GL; Miller LL; Von Hoff DD
    Cancer; 1999 Feb; 85(4):786-95. PubMed ID: 10091755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
    Saltz LB; Cox JV; Blanke C; Rosen LS; Fehrenbacher L; Moore MJ; Maroun JA; Ackland SP; Locker PK; Pirotta N; Elfring GL; Miller LL
    N Engl J Med; 2000 Sep; 343(13):905-14. PubMed ID: 11006366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors.
    Furman WL; Crews KR; Billups C; Wu J; Gajjar AJ; Daw NC; Patrick CC; Rodriguez-Galindo C; Stewart CF; Dome JS; Panetta JC; Houghton PJ; Santana VM
    J Clin Oncol; 2006 Feb; 24(4):563-70. PubMed ID: 16446328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
    Soepenberg O; Dumez H; Verweij J; de Jong FA; de Jonge MJ; Thomas J; Eskens FA; van Schaik RH; Selleslach J; Ter Steeg J; Lefebvre P; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
    Clin Cancer Res; 2005 Feb; 11(4):1504-11. PubMed ID: 15746053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer.
    Chester JD; Joel SP; Cheeseman SL; Hall GD; Braun MS; Perry J; Davis T; Button CJ; Seymour MT
    J Clin Oncol; 2003 Mar; 21(6):1125-32. PubMed ID: 12637480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.